ArticleBiomedical reports2014
Association of the interleukin-18 -137 C/G, -607 A/C polymorphisms with type 1 diabetes: A meta-analysis.
Article in Biomedical reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 5 citations in OpenAlex.
- Immune Response and Lipid Metabolism Gene Polymorphisms Are Associated with the Risk of Obesity in Middle-Aged and Elderly Patients.Journal of personalized medicine · 2022Article
- Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: Biological role in induction, regulation, and treatment.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Published data on the association between interleukin (IL)-18 gene polymorphisms (-137 C/G, -607 A/C) and type 1 diabetes (T1D) risk are inconclusive. To obtain a more precise estimation of the association between the IL-18 gene polymorphisms and T1D, a meta-analysis was performed. A total of 11 studies including 5,945 cases and 6,404 controls were included in the analysis of the association between -137 C/G and T1D risk. No significant association between -137 C/G and T1D risk was observed in the total population [C vs. G: odds ratio (OR)=1.02, 95% confidence interval (CI)=0.87-1.20; CC + CG vs. GG: OR=1.05, 95% CI=0.87-1.25; CC vs. CG + GG: OR=0.96, 95% CI=0.68-1.36]. No significant association was identified in the stratified analysis for all the genetic models in the European population. Concerning -607 A/C, 10 studies involving 3,048 patients and 3,377 controls were included in this meta-analysis. When all the studies were pooled, the results showed no evidence for a significant association between IL-18 -607 A/C polymorphism and T1D risk (A vs. C: OR=0.93, 95% CI=0.81-1.06; AA + AC vs. CC: OR=0.99, 95% CI=0.89-1.10; AA vs. AC + CC: OR=0.81, 95% CI=0.60-1.09). In addition, similar results were obtained in the subgroup analysis based on ethnicity. In summary, the present meta-analysis suggests a lack of association between the two polymorphisms (-137 C/G, -607 A/C) in the IL-18 gene and T1D. Due to the limitation of the number of the studies, the conclusions drawn should be considered with caution. Larger scale primary studies are required to evaluate the association between IL-18 gene polymorphisms and T1D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.